The stable gastric pentadecapeptide BPC 157, an original cytoprotective antiulcer peptide that is used in ulcerative colitis and recently in a multiple sclerosis trial and that has an LD1 that has not been achieved [1,2,3,4,5,6,7,8,9,10,11], is known to have pleiotropic beneficial effects [1,2,3,4,5,6,7,8,9,10,11] and to interact with several molecular pathways [2, 27,28,29,30,31,32]
Cost vs
NICE guidelines for type 2 diabetes (NG28) recommend reviewing GLP-1 treatment at around 6 months and continuing only if there has been a meaningful reduction in HbA1c (typically at least 11 mmol/mol [1%]) and weight loss of at least 3% of initial body weight
Use the peptide cost calculator with your specific source pricing to get an accurate estimate